Want to see JP:197A full AI Analyst Report?
197A Stock Chart & Stats
¥509.00
¥4.00(0.67%)
At close: 4:00 PM EST
¥509.00
¥4.00(0.67%)
Day’s Range― - ―
52-Week Range¥463.00 - ¥603.00
Previous CloseN/A
Volume864.10K
Average Volume (3M)400.80K
Market Cap
¥50.79B
Enterprise Value¥69.37K
Total Cash (Recent Filing)¥5.89B
Total Debt (Recent Filing)¥21.71B
Price to Earnings (P/E)23.4
Beta0.43
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.92%
Share Statistics
EPS (TTM)20.24
Shares Outstanding106,691,690
10 Day Avg. Volume355,040
30 Day Avg. Volume400,796
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.14
Price to Sales (P/S)2.94
P/FCF Ratio25.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)44.02
Revenue Forecast (FY)¥18.43B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthA 5.79% top-line increase shows steady end-market demand and product traction. Persistent revenue growth supports reinvestment in R&D and sales, improves operating leverage, and reduces reliance on one-off gains, strengthening the business over a 2–6 month horizon.
High Profitability And MarginsRobust gross, net, EBIT and EBITDA margins reflect operational efficiency and pricing power in its specialty medical niche. Durable margin structure underpins ongoing cash generation and resilience to cyclical pressures, enabling sustained funding for capex and strategic initiatives.
Solid Equity Base & Strong ROEA solid equity position and impressive ROE indicate efficient use of shareholder capital and financial strength. This provides flexibility to fund growth, absorb shocks, or pursue strategic investments without immediate need for external capital, supporting medium-term stability.
Bears Say
Rising Total DebtAn increasing debt load raises leverage and interest-cost sensitivity, potentially weakening interest coverage and reducing financial flexibility. Higher indebtedness can limit ability to invest or return cash to shareholders and increases refinancing and covenant risks over the medium term.
Cash Flow VolatilityWhile free cash flow has recently improved, historical volatility and a prior year of negative operating cash flow indicate uneven cash conversion. This irregularity can constrain dividends, capex planning and buffer capacity, requiring conservative liquidity management during downturns.
Gross Profit DeclineA year-over-year dip in gross profit points to rising input costs or margin pressure. In medical specialties, sustained cost inflation or limited pricing power could erode profitability, forcing operational adjustments or margin-restoring measures that weigh on longer-term earnings stability.
Tauns Laboratories, Inc. News
197A FAQ
What was Tauns Laboratories, Inc.’s price range in the past 12 months?
Tauns Laboratories, Inc. lowest stock price was ¥463.00 and its highest was ¥603.00 in the past 12 months.
What is Tauns Laboratories, Inc.’s market cap?
Tauns Laboratories, Inc.’s market cap is ¥50.79B.
When is Tauns Laboratories, Inc.’s upcoming earnings report date?
Tauns Laboratories, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 12 days.
How were Tauns Laboratories, Inc.’s earnings last quarter?
Tauns Laboratories, Inc. released its earnings results on May 14, 2026. The company reported ¥3.49 earnings per share for the quarter, beating the consensus estimate of N/A by ¥3.49.
Is Tauns Laboratories, Inc. overvalued?
According to Wall Street analysts Tauns Laboratories, Inc.’s price is currently Overvalued.
Does Tauns Laboratories, Inc. pay dividends?
Tauns Laboratories, Inc. pays a Annually dividend of ¥14 which represents an annual dividend yield of 5.92%. See more information on Tauns Laboratories, Inc. dividends here
What is Tauns Laboratories, Inc.’s EPS estimate?
Tauns Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tauns Laboratories, Inc. have?
Tauns Laboratories, Inc. has 106,691,690 shares outstanding.
What happened to Tauns Laboratories, Inc.’s price movement after its last earnings report?
Tauns Laboratories, Inc. reported an EPS of ¥3.49 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.798%.
Which hedge fund is a major shareholder of Tauns Laboratories, Inc.?
Currently, no hedge funds are holding shares in JP:197A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tauns Laboratories, Inc.
TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an extensive selection of instruments, covering industrial, medical, physical, and chemical measurement applications. Founded in April 1987, the company maintains its principal office in Izunokuni, Japan.
Technical Analysis
Shin Nippon Biomedical Laboratories, Ltd.
―
Eiken Chemical Co., Ltd.
―
JCR Pharmaceuticals Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Kitazato Corporation
―